Limits...
Toric phakic implantable collamer lens for correction of astigmatism: 1-year outcomes.

Mertens EL - Clin Ophthalmol (2011)

Bottom Line: More than 60% of the eyes gained ≥1 line of BCVA (17 eyes, safety index of 1.14).For J(0) and J(45), 97.7% and 83.7% were within ±0.50 D, respectively.The results of the present study support the safety, efficacy, and predictability of toric implantable collamer lens implantation to treat moderate to high myopic astigmatism.

View Article: PubMed Central - PubMed

Affiliation: Medipolis Eye Centre, Antwerp, Belgium.

ABSTRACT

Purpose: The purpose of this study was to assess predictability, efficacy, safety and stability in patients who received a toric implantable collamer lens to correct moderate to high myopic astigmatism.

Methods: Forty-three eyes of 23 patients underwent implantation of a toric implantable collamer lens (STAAR Surgical Inc) for astigmatism correction. Mean spherical refraction was -4. 98 ± 3.49 diopters (D) (range: 0 to -13 D), and mean cylinder was -2.62 ± 0.97 D (range: -1.00 to -5.00 D). Main outcomes measures evaluated during a 12-month follow-up included uncorrected visual acuity (UCVA), refraction, best-corrected visual acuity (BCVA), vault, and adverse events.

Results: At 12 months the mean Snellen decimal UCVA was 0.87 ± 0.27 and mean BCVA was 0.94 ± 0.21, with an efficacy index of 1.05. More than 60% of the eyes gained ≥1 line of BCVA (17 eyes, safety index of 1.14). The treatment was highly predictable for spherical equivalent (r(2) = 0.99) and astigmatic components: J(0) (r(2) = 0.99) and J(45) (r(2) = 0.90). The mean spherical equivalent dropped from -7.29 ± 3.4 D to -0.17 ± 0.40 D at 12 months. Of the attempted spherical equivalent, 76.7% of the eyes were within ±0.50 D and 97.7% eyes were within ±1.00 D, respectively. For J(0) and J(45), 97.7% and 83.7% were within ±0.50 D, respectively.

Conclusion: The results of the present study support the safety, efficacy, and predictability of toric implantable collamer lens implantation to treat moderate to high myopic astigmatism.

No MeSH data available.


Related in: MedlinePlus

Uncorrected distance visual acuity (UCVA) and best-corrected distance visual acuity (BCVA) before and after toric implantable collamer lens implantation.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3065582&req=5

f8-opth-5-369: Uncorrected distance visual acuity (UCVA) and best-corrected distance visual acuity (BCVA) before and after toric implantable collamer lens implantation.

Mentions: In relation to the efficacy, Figure 8 shows the changes in UCVA and BCVA. Before surgery the mean Snellen decimal UCVA was 0.09 ± 0.07 (range: 0.05 to 0.2) while BCVA was 0.83 ± 0.18 (range: 0.5 to 1.2). At 12 months, the mean UCVA was 0.87 ± 0.27 (range 0.2 to 1.2) and the mean BCVA was 0.94 ± 0.21 (range 0.5 to 1.2). The overall efficacy was 1.05. At the 12-month examination 25 (58.1%) eyes had 20/20 or better UCVA, compared with 13 (30.2%) BCVA at baseline. Furthermore, 31 (72%) eyes had 12-month postoperative UCVA equal to or better than preoperative BCVA and 12 (28%) eyes having 12-month postoperative UCVA lower than preoperative BCVA.


Toric phakic implantable collamer lens for correction of astigmatism: 1-year outcomes.

Mertens EL - Clin Ophthalmol (2011)

Uncorrected distance visual acuity (UCVA) and best-corrected distance visual acuity (BCVA) before and after toric implantable collamer lens implantation.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3065582&req=5

f8-opth-5-369: Uncorrected distance visual acuity (UCVA) and best-corrected distance visual acuity (BCVA) before and after toric implantable collamer lens implantation.
Mentions: In relation to the efficacy, Figure 8 shows the changes in UCVA and BCVA. Before surgery the mean Snellen decimal UCVA was 0.09 ± 0.07 (range: 0.05 to 0.2) while BCVA was 0.83 ± 0.18 (range: 0.5 to 1.2). At 12 months, the mean UCVA was 0.87 ± 0.27 (range 0.2 to 1.2) and the mean BCVA was 0.94 ± 0.21 (range 0.5 to 1.2). The overall efficacy was 1.05. At the 12-month examination 25 (58.1%) eyes had 20/20 or better UCVA, compared with 13 (30.2%) BCVA at baseline. Furthermore, 31 (72%) eyes had 12-month postoperative UCVA equal to or better than preoperative BCVA and 12 (28%) eyes having 12-month postoperative UCVA lower than preoperative BCVA.

Bottom Line: More than 60% of the eyes gained ≥1 line of BCVA (17 eyes, safety index of 1.14).For J(0) and J(45), 97.7% and 83.7% were within ±0.50 D, respectively.The results of the present study support the safety, efficacy, and predictability of toric implantable collamer lens implantation to treat moderate to high myopic astigmatism.

View Article: PubMed Central - PubMed

Affiliation: Medipolis Eye Centre, Antwerp, Belgium.

ABSTRACT

Purpose: The purpose of this study was to assess predictability, efficacy, safety and stability in patients who received a toric implantable collamer lens to correct moderate to high myopic astigmatism.

Methods: Forty-three eyes of 23 patients underwent implantation of a toric implantable collamer lens (STAAR Surgical Inc) for astigmatism correction. Mean spherical refraction was -4. 98 ± 3.49 diopters (D) (range: 0 to -13 D), and mean cylinder was -2.62 ± 0.97 D (range: -1.00 to -5.00 D). Main outcomes measures evaluated during a 12-month follow-up included uncorrected visual acuity (UCVA), refraction, best-corrected visual acuity (BCVA), vault, and adverse events.

Results: At 12 months the mean Snellen decimal UCVA was 0.87 ± 0.27 and mean BCVA was 0.94 ± 0.21, with an efficacy index of 1.05. More than 60% of the eyes gained ≥1 line of BCVA (17 eyes, safety index of 1.14). The treatment was highly predictable for spherical equivalent (r(2) = 0.99) and astigmatic components: J(0) (r(2) = 0.99) and J(45) (r(2) = 0.90). The mean spherical equivalent dropped from -7.29 ± 3.4 D to -0.17 ± 0.40 D at 12 months. Of the attempted spherical equivalent, 76.7% of the eyes were within ±0.50 D and 97.7% eyes were within ±1.00 D, respectively. For J(0) and J(45), 97.7% and 83.7% were within ±0.50 D, respectively.

Conclusion: The results of the present study support the safety, efficacy, and predictability of toric implantable collamer lens implantation to treat moderate to high myopic astigmatism.

No MeSH data available.


Related in: MedlinePlus